Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,869 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Multiple Sclerosis, Hypertension
Interventions: Home-based aerobic training; Behavioral
Lead sponsor: University of Massachusetts, Boston; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Neuroendocrine Tumors
Interventions: vatalanib; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Kenner, Louisiana

Conditions: Acute Myelogenous Leukemia
Interventions: SAR103168; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Atlanta, Georgia • New York, New York • Houston, Texas

Conditions: Neoplasms
Interventions: RO6874813; Biological
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Migraine
Interventions: Metformin, Matching Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Diabetes Mellitus, Type 2
Interventions: Alogliptin Benzoate, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 34
States / cities: Little Rock, Arkansas • Los Angeles, California • Palmdale, California + 31 more

Conditions: Mechanical Ventilation, Sedation and Analgesia, Critical Care, Intensive Care
Interventions: fentanyl, Hydromorphone; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumour
Interventions: Savolitinib, Itraconazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Glendale, California

Conditions: Antithrombin III Deficiency
Interventions: Recombinant human antithrombin (rhAT); Biological
Lead sponsor: rEVO Biologics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: New Haven, Connecticut • St Louis, Missouri • New York, New York

Conditions: Ulcerative Colitis
Interventions: BBT-401-1S first and then Placebo, Placebo first and then BBT-401-1S; Drug
Lead sponsor: Bridge Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 11
States / cities: Sacramento, California • Ventura, California • Boca Raton, Florida + 8 more

Conditions: Acute Lung Injury, Adult Respiratory Distress Syndrome, Kidney Injury
Interventions: Volume-Cycled Assist-Control (AC) mode, Airway Pressure Release Ventilation (APRV) mode; Device
Lead sponsor: University of Tennessee, Chattanooga; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Chronic Diseases
Interventions: smoking cessation; Behavioral
Lead sponsor: National Institutes of Health (NIH); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 443 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Multiple Myeloma
Interventions: Ixazomib citrate; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 6
States / cities: Scottsdale, Arizona • West Hollywood, California • Chicago, Illinois + 3 more

Conditions: Multiple Myeloma
Interventions: Siltuximab11 mg/kg, Siltuximab 8.3 mg/kg or 11 mg/kg, Velcade (bortezomib), Melphalan, Prednisone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 4
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: Cigarette Smoking
Interventions: E-cigarette (EC), Nicotine Replacement Therapy (NRT), Harm-Reduction Counseling, Ecological Momentary Intervention (EMI) Text Messaging; Other · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Sarcoma, Alveolar Soft Part
Interventions: Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years to 120 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gastric Cancer
Interventions: Cisplatin, Capecitabine, Telatinib; Drug
Lead sponsor: ACT Biotech, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: San Francisco, California • Macon, Georgia • Philadelphia, Pennsylvania + 2 more

Conditions: Metastatic Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions: DZ-002 - 5 mg/kg, 6 mg/kg, or 7 mg/kg; Drug
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions: Metformin 500 Mg Oral Tablet, up to 4 tablets a day, Placebo oral tablet identical to metformin, up to 4 tablets a day; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 30 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Fatigue
Interventions: Open-label placebo intervention; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Osteoarthritis, Knee
Interventions: BION; Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Symptomatic Neurogenic Orthostatic Hypotension
Interventions: Droxidopa capsules, Placebo capsules; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 168
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Standard of care; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 78
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more

Conditions: Posttraumatic Stress Disorder, Cancer
Interventions: Cancer Distress Coach Mobile App; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 569 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Vascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With Hypertension

Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes

A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors

Metformin for the Prevention of Episodic Migraine (MPEM)

Phase 3 Alogliptin Pediatric Study

Fentanyl Versus Hydromorphone in Patients on Mechanical Ventilation

A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole

Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery

Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

Airway Pressure Release Ventilation (APRV) Compared to ARDSnet Ventilation

Longitudinal Care: Smoking Reduction to Aid Cessation

Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

E-cigarettes for Harm Reduction Among Smokers With Serious Mental Illness

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer

Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate

Metformin Treatment in Progressive Multiple Sclerosis

The Use of an Open Label Placebo to Treat Cancer Related Fatigue in Cancer Survivors

BION Treatment of Knee Osteoarthritis

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

Open Label Study of Long Term Evaluation Against LDL-C Trial

Cancer Distress Coach Mobile App Trial